Axon Enterprise, Inc $AXON Shares Sold by Cetera Investment Advisers

Cetera Investment Advisers decreased its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 3.6% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 38,234 shares of the biotechnology company’s stock after selling 1,446 shares during the quarter. Cetera Investment Advisers’ holdings in Axon Enterprise were worth $16,238,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of AXON. Vanguard Group Inc. grew its holdings in shares of Axon Enterprise by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 9,367,224 shares of the biotechnology company’s stock worth $5,319,928,000 after acquiring an additional 53,060 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Axon Enterprise by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 2,226,159 shares of the biotechnology company’s stock valued at $1,265,657,000 after purchasing an additional 35,544 shares during the period. Baillie Gifford & Co. increased its stake in Axon Enterprise by 1,198.7% in the 4th quarter. Baillie Gifford & Co. now owns 1,642,578 shares of the biotechnology company’s stock worth $932,869,000 after purchasing an additional 1,516,099 shares in the last quarter. Sands Capital Management LLC raised its holdings in Axon Enterprise by 11.6% during the 4th quarter. Sands Capital Management LLC now owns 1,609,436 shares of the biotechnology company’s stock worth $914,047,000 after buying an additional 167,095 shares during the period. Finally, Wellington Management Group LLP lifted its stake in Axon Enterprise by 326.9% during the fourth quarter. Wellington Management Group LLP now owns 1,539,738 shares of the biotechnology company’s stock valued at $874,463,000 after buying an additional 1,179,038 shares in the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $547.65 on Wednesday. The firm has a market cap of $44.14 billion, a price-to-earnings ratio of 219.94, a P/E/G ratio of 10.72 and a beta of 1.38. Axon Enterprise, Inc has a 1 year low of $339.01 and a 1 year high of $885.91. The company has a current ratio of 2.27, a quick ratio of 1.93 and a debt-to-equity ratio of 0.49. The business has a fifty day simple moving average of $488.89 and a 200 day simple moving average of $477.58.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a return on equity of 3.78% and a net margin of 6.90%.The firm had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.90 million. During the same quarter in the previous year, the company posted $1.47 earnings per share. The business’s quarterly revenue was up 33.7% compared to the same quarter last year. As a group, sell-side analysts predict that Axon Enterprise, Inc will post 1.63 earnings per share for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In related news, President Joshua Isner sold 13,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $488.45, for a total transaction of $6,349,850.00. Following the transaction, the president owned 169,125 shares of the company’s stock, valued at approximately $82,609,106.25. This trade represents a 7.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 564 shares of Axon Enterprise stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $478.97, for a total transaction of $270,139.08. Following the completion of the sale, the director owned 3,632 shares of the company’s stock, valued at $1,739,619.04. This trade represents a 13.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 58,989 shares of company stock worth $30,527,983 over the last quarter. Insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on AXON. UBS Group dropped their target price on shares of Axon Enterprise from $570.00 to $440.00 and set a “neutral” rating on the stock in a research report on Thursday, May 7th. Barclays decreased their price objective on shares of Axon Enterprise from $682.00 to $523.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Morgan Stanley set a $600.00 target price on shares of Axon Enterprise in a research note on Thursday, May 7th. The Goldman Sachs Group set a $535.00 target price on shares of Axon Enterprise in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada restated an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, July 21st. Fifteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $725.25.

Axon Enterprise Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.